XML 57 R21.htm IDEA: XBRL DOCUMENT
v3.20.1

Stock Purchase and Award Plans | 12 Months Ended
--- | ---
Apr. 24, 2020
Share-based Payment Arrangement [Abstract] |
Stock Purchase and Award Plans | Stock Purchase and Award Plans The Medtronic, Inc. 2013 Stock Award and Incentive Plan was originally approved by the Company's shareholders in August 2013. In January 2015, the Company's Board of Directors approved an amendment to and assumption of the Medtronic, Inc. 2013 Stock Award and Incentive Plan, which created the Medtronic plc 2013 Stock Award and Incentive Plan (2013 Plan). In fiscal year 2020, the Company granted stock awards under the 2013 Plan. The 2013 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April 24, 2020, there were approximately 41 million shares available for future grants under the 2013 Plan. Share Options Options are granted at the exercise price, which is equal to the closing price of the Company’s ordinary shares on the grant date. The majority of the Company’s options are non-qualified options with a 10-year life and a 4-year ratable vesting term. Restricted Stock Restricted stock awards and restricted stock units (collectively referred to as restricted stock) are granted to officers and key employees. At April 24, 2020, the Company does not have any outstanding restricted stock awards. Beginning in fiscal year 2018, restricted stock units have a 4-year ratable vesting term. Restricted stock units issued prior to fiscal year 2018 cliff vest after four years. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The Company also grants shares of performance-based restricted stock units that typically cliff vest after three years only if the Company has also achieved certain performance objectives. Performance awards are expensed over the performance period based on the probability of achieving the performance objectives. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period. Employees Stock Purchase Plan The Medtronic plc Amended and Restated 2014 Employees Stock Purchase Plan (ESPP) allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company’s ESPP is equal to the 15 percent discount the employee receives at the end of the calendar quarter purchase period. Employees may contribute between 2 percent and 10 percent of their wages or the statutory limit under the U.S. Internal Revenue Code toward the purchase of newly-issued ordinary shares of the Company at 85 percent of its market value at the end of the calendar quarter purchase period. Employees purchased 2 million shares at an average price of $86.34 per share in fiscal year 2020. At April 24, 2020, plan participants had approximately $14 million withheld to purchase the Company's ordinary shares at 85 percent of its market value on June 30, 2020, the last trading day before the end of the calendar quarter purchase period. At April 24, 2020, approximately 11 million ordinary shares were available for future purchase under the ESPP. Stock Option Valuation Assumptions The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price, and expected dividends. The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:
| Fiscal Year |  |  |  |
| 2020 |  | 2019 |  | 2018
Weighted average fair value of options granted | $ | 15.49 |  |  | $ | 14.77 |  |  | $ | 13.71 |
Assumptions used: |  |  |  |  |
Expected life (years)(1) | 6.1 |  | 6.1 |  | 6.2
Risk-free interest rate(2) | 1.88 | % |  | 2.90 | % |  | 2.00 | %
Volatility(3) | 17.97 | % |  | 17.77 | % |  | 19.51 | %
Dividend yield(4) | 2.09 | % |  | 2.25 | % |  | 2.19 | %
(1)The Company analyzes historical employee stock option exercise and termination data to estimate the expected life assumption. The Company calculates the expected life assumption using the midpoint scenario, which combines historical exercise data with hypothetical exercise data, as the Company believes this data currently represents the best estimate of the expected life of a new employee option. (2)The rate is based on the grant date yield of a zero-coupon U.S. Treasury bond whose maturity period equals the expected term of the option. (3)Expected volatility is based on a blend of historical volatility and an implied volatility of the Company’s ordinary shares. Implied volatility is based on market traded options of the Company’s ordinary shares. (4)The dividend yield rate is calculated by dividing the Company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. Stock-Based Compensation Expense The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, and ESPP in fiscal years 2020, 2019, and 2018:
| Fiscal Year |  |  |  |
(in millions) | 2020 |  | 2019 |  | 2018
Stock options | $ | 61 |  |  | $ | 72 |  |  | $ | 132 |
Restricted stock | 205 |  |  | 189 |  |  | 185 |
Employee stock purchase plan | 31 |  |  | 29 |  |  | 27 |
Total stock-based compensation expense | $ | 297 |  |  | $ | 290 |  |  | $ | 344 |
Cost of products sold | $ | 28 |  |  | $ | 30 |  |  | $ | 44 |
Research and development expense | 36 |  |  | 36 |  |  | 38 |
Selling, general, and administrative expense | 233 |  |  | 224 |  |  | 262 |
Total stock-based compensation expense | 297 |  |  | 290 |  |  | 344 |
Income tax benefits | (51) |  |  | (54) |  |  | (82) |
Total stock-based compensation expense, net of tax | $ | 246 |  |  | $ | 236 |  |  | $ | 262 |
Stock Options The following table summarizes all stock option activity, including activity from options assumed or issued as a result of acquisitions, during fiscal year 2020:
| Options (in thousands) |  | Wtd. Avg. Exercise Price |  | Wtd. Avg. Remaining Contractual Term (in years) |  | Aggregate Intrinsic Value (in millions)
Outstanding at April 26, 2019 | 31,677 |  |  | $ | 71.52 |  |  |  |  |
Granted | 4,349 |  |  | 103.26 |  |  |  |  |
Exercised | (8,165) |  |  | 62.49 |  |  |  |  |
Expired/Forfeited | (793) |  |  | 90.74 |  |  |  |  |
Outstanding at April 24, 2020 | 27,068 |  |  | 78.70 |  |  | 5.9 |  | $ | 574 |
Expected to vest at April 24, 2020 | 8,742 |  |  | 94.12 |  |  | 8.4 |  | 60 |
Exercisable at April 24, 2020 | 17,878 |  |  | 70.70 |  |  | 4.5 |  | 512 |
The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2020, 2019, and 2018:
| Fiscal Year |  |  |  |
(in millions) | 2020 |  | 2019 |  | 2018
Cash proceeds from options exercised | $ | 484 |  |  | $ | 825 |  |  | $ | 250 |
Intrinsic value of options exercised | 349 |  |  | 383 |  |  | 248 |
Tax benefit related to options exercised | 75 |  |  | 78 |  |  | 75 |
Unrecognized compensation expense related to outstanding stock options at April 24, 2020 was $61 million and is expected to be recognized over a weighted average period of 2.5 years. Restricted Stock The following table summarizes restricted stock activity, including activity from restricted stock assumed or issued as a result of acquisitions, during fiscal year 2020:
| Units (in thousands) |  | Wtd. Avg. Grant Price
Nonvested at April 26, 2019 | 7,996 |  |  | $ | 84.78 |
Granted | 3,205 |  |  | 103.52 |
Vested | (2,910) |  |  | 83.30 |
Forfeited | (666) |  |  | 89.75 |
Nonvested at April 24, 2020 | 7,625 |  |  | 92.52 |
The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2020, 2019, and 2018:
| Fiscal Year |  |  |  |
(in millions, except per share data) | 2020 |  | 2019 |  | 2018
Weighted-average grant-date fair value per restricted stock | $ | 103.52 |  |  | $ | 88.78 |  |  | $ | 83.88 |
Fair value of restricted stock vested | 242 |  |  | 174 |  |  | 160 |
Tax benefit related to restricted stock vested | 62 |  |  | 45 |  |  | 63 |
Unrecognized compensation expense related to restricted stock as of April 24, 2020 was $353 million and is expected to be recognized over a weighted average period of 2.5 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration